Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

Abstract

The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with left ventricular systolic dysfunction. There described the clinical case with emphasis on possibility of inclusion in conservative treatment scheme of TMZ MB to poly morbid elderly patient with severe ischemic heart disease.

Keywords

• ischemic heart disease
• multivessel lesion
• systolic dysfunction
• drug treatment
• trimetazidine modified release